发明名称 |
Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
摘要 |
The present invention relates to a beneficial treatment of tumours in patients suffering from NSCLC, and to a clinical marker useful as as predictive variable of the responsiveness of tumours in patients suffering from NSCLC. The present invention further relates to a method for selecting patients likely to respond to a given therapy, wherein said method optionally comprises the use of a specific clinical marker. The present invention further relates to a method for delaying disease progression and/or prolonging patient survival of NSCLC patients, wherein said method comprises the use of a specific clinical marker. |
申请公布号 |
US2014350022(A1) |
申请公布日期 |
2014.11.27 |
申请号 |
US201414267978 |
申请日期 |
2014.05.02 |
申请人 |
GASCHLER-MARKEFSKI Birgit;KAISER Ralf |
发明人 |
GASCHLER-MARKEFSKI Birgit;KAISER Ralf |
分类号 |
A61K31/496;A61K45/06 |
主分类号 |
A61K31/496 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for the treatment of non-small cell lung cancer in a patient who has received prior treatment with an anti-tumour therapy other than with nintedanib, which method comprises treating said patient with a treatment regimen comprising the administration of nintedanib or a pharmaceutically acceptable salt thereof, wherein the patient to be treated is selected for treatment on the basis of having shown progression of the cancer within a period of 9 months or less after the initiation of said prior treatment. |
地址 |
Ingoldingen DE |